CUE
Cue Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$16.08
−3.77%Year over year
Reported trailing growth
- Revenue
- +354.4%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- -77.1%
- Operating cash flow
- -77.8%
Forward estimates
Based on analyst estimates
- Revenue
- -97.3%
- EBITDA
- +88.4%
- EPS
- +93.5%
Three-year CAGR
- Revenue
- +180.5%
- EBITDA
- +34.0%
- EBIT
- +36.1%
- Net income
- +34.6%
- EPS
- +61.1%
- Free cash flow
- +39.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026